Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Data from the study, conducted over roughly 3.5 years, suggest that GLP-1 drugs compared to other diabetes ... medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug for weight management. The Food and Drug Administration’s approval ...

The study found that GLP-1-based drugs are effective for weight loss in ... claims database as initiating either denosumab or oral bisphosphonates for osteoporosis. Since fracture morbidity ...

The new oral drug is viewed as a key product for Novo Nordisk as it tries to case Eli Lilly's Trulicity (dulaglutide), a once-weekly GLP-1 drug that is the market leader in the class with sales of ...

There's no doubt that Roche is playing catchup in the category, one of a lengthening list of pharma companies ... a once-daily formulation of its oral GLP-1 drug danuglipron as its preferred ...